Drug delivery technology company Concept Medical Inc announced on Thursday that the first patient has been enrolled in the 'MAGICAL BTK' randomised controlled trial of MagicTouch PTA Sirolimus Coated Balloon (SCB) versus standard balloon angioplasty in the treatment of below the knee arterial disease.

This initiation of the US Investigational Device Exemption (IDE) pivotal trial marks the beginning of Concept Medical's peripheral clinical trial programme in the United States.

With the ongoing IDE study for MagicTouch SCB in coronary artery disease, Concept Medical is now actively enrolling in US clinical trials in both coronary and peripheral interventions, with the aim of improving patient outcomes and expanding therapeutic choices.